Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclaimer
- Talk outline
- Pain pathophysiology
- Pain classification
- Pharmacometrics
- Quantitative disease-drug-trial model
- Pain modeling - placebo effect
- Pain modeling - drug effect
- Examples of exposure-response models
- Pain modeling - trial effect (drop out)
- Pharmcometrics in clinical patient care
- Navigator display window - PK/PD Information
- PK & PD interaction - propofol & remifentanil
- Case study 1 - fixed dose combination
- Fixed-dose combination products - rule
- Examples - ultracept & vicodin
- Study design
- Buprenorphine & fentanyl - additive interaction
- Pain relief in fixed-dose combination products
- Case study 2 - acetaminophen pediatric dosing
- Acetaminophen pediatric dosing history
- Acetaminophen study methods
- Acetaminophen PK - Cmax
- Acetaminophen PK - AUC
- Fever reduction - dose response
- Pain reduction - dose response
- Summary
Topics Covered
- What is pain
- Classification of pain
- What is pharmacometrics
- Modeling in chronic & acute pain
- Pharmacometrics in clinical patient care
- Drug dosing advisory displays
- Pharmacometrics in opioid treatment
- Case examples: fixed dose combination
- Case examples: acetaminophen pediatric dosing regimen
Talk Citation
Wang, Y., Liu, J., Zhu, H. and Ji, P. (2015, January 19). Pharmacometrics in pain management [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 11, 2024, from https://doi.org/10.69645/ZFPT4174.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Yaning Wang has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Jiang Liu has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Hao Zhu has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Ping Ji has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Pharmacometrics in pain management
Published on January 19, 2015
28 min
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, my
name is Yaning Wang.
I'll present the pharmacometrics
in pain management
on behalf of the author list.
0:10
First of all, I would like to
point out that opinions expressed
in this presentation
are those of the authors
and may not necessarily
be consistent with some
of the current product
development standards
of the regulatory agencies.
To obtain the most current standards
or advice for drug development,
for opioids or any
products being developed,
the readers should contact
the regulatory agency.
0:37
In this talk, I will start with
the background about pain and pain
management, followed by
a general introduction
of the modeling in
chronic and acute pain.
Then I will talk about the
application of pharmacometrics
in clinical patient care
and opioid treatments.
Then I will use two case studies to
demonstrate how pharmacometrics can
be applied in the regulatory
decision making process.
And finally, I will
finish with a summary.
1:05
Pain is a dynamic phenomenon.
It is defined by the International
Association for the Study of Pain
as unpleasant sensory and emotional
experience associated with actual
or potential tissue damage or is
described in terms of such damage.
The sensation results
from nerve impulses
reaching the cerebral cortex
via specific neural pathways
and is modulated at all
levels of peripheral
and central nervous systems.
The prevalence of chronic pain is
high in industrialized countries.
It has been estimated that
about 100 million adults suffer
from chronic pain in the United
States alone, with treatment costs
and loss of productivity added up
to 635 billion per year. Globally,
about 20% of adults suffer
from pain and 10% of adults
become new chronic pain
patients each year.
Life quality of a
patient with chronic pain
is largely compromised because
of the persistent nature
of the symptom.